364 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (364)
- Addiction (2)
- (-) Allergy, Asthma, & Immunology (1)
- Autoimmune Disorders (2)
- Blood Disorders (1)
- Bone & Muscle (2)
- Cancer (109)
- Child Development (1)
- COVID-19 (Coronavirus) (10)
- Diabetes (9)
- Ear, Nose and Throat (6)
- Endocrine & Metabolic Disease (2)
- Gastrointestinal and Digestive Diseases (3)
- Hair and Skin Disorders (1)
- Healthy Volunteers (44)
- Heart Disease (25)
- Infectious Disease (11)
- Liver Disease (14)
- Lung Disease (3)
- Neurological Disorders (45)
- Nutrition (1)
- Obesity (8)
- Obstetrics & Gynecology (12)
- Pediatrics (26)
- Psychiatric Disorders (8)
- Rehabilitation (1)
- Stroke (2)
- Transplant (15)
Displaying 1 - 7 of 7
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Currently Recruiting
This study is a Phase 1 clinical trial, which means it is the first stage of testing a new drug in humans to evaluate its safety, determine how the body processes it, and identify any potential side effects. The drug being studied, DZD6008, is investigational, meaning it has not been approved by the U.S. Food and Drug Administration (FDA). This study is…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Currently Recruiting
The purpose of this study is to understand more about the combination of amivantamab and lazertinib in non-small cell lung cancer (NSCLC) who have a specific mutation in the EGFR (epidermal growth factor receptor) gene and have not had prior treatment for their disease. The Food and Drug Administration (FDA) has not approved the combination of amivantamab…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Currently Recruiting
The purpose of this study is to evaluate the safety and effectiveness of an experimental drug, BDTX1535, which is not yet approved by the United States Food and Drug Administration (FDA), intreating patients with advanced solid tumors with changes in a protein named epidermal growth factor receptor (EGFR), which may or may not help your condition during…
Condition: Allergy, Asthma, & Immunology / Asthma
Investigator: Meyer Kattan, MD
Status: Currently Recruiting
We are interested in learning more about these diseases and how to treat them. Our research program is conducting several studies including: a study to learn if treatment with a drug named dupilumab can help reduce asthma attacks in children, a study to observe a specific type of irritation in the lungs and how it relates to asthma symptoms, and more! If…
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Currently Recruiting
The purpose of this study is to find out if JNJ-86974680 taken by itself or together with Cetrelimab and radiotherapy can cause side effects which are unexpected or unwanted reactions. This is the first time that JNJ-86974680 is being used in people. Radiotherapy is also part of the study treatment and not part of your standard of care. JNJ-86974680 and…
Condition: Cancer / Lung Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose this study to learn more about if a medication called durvalumab will work and be safe for the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) with certain genetic changes when given in combination with tremelimumab and standard chemotherapy. Additionally, this study is being done to better…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Currently Recruiting
This study will compare the effectiveness of osimertinib alone to the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene for the epidermal growth factor receptor (EGFR). Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. This…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE